Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 29;13(3):684-688.
doi: 10.21037/tlcr-23-777. Epub 2024 Mar 8.

Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors

Hidenori Kitai  1 , Hiromichi Ebi  2   3
Affiliations
Editorial

Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors

Hidenori Kitai et al. Transl Lung Cancer Res. .
No abstract available

Keywords: FGFR inhibitor; Fibroblast growth factor receptor 1 (FGFR1); biomarker; squamous cell lung cancer (SQCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-777/coif). H.E. reports honoraria from AMGEN, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Incyte, Kyowa-Kirin, Merck Serono, Takeda, and Taiho. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Tail-to-tail rearrangements within or close to the FGFR1 gene associated with FGFR1 dependency. FGFR1, fibroblast growth factor receptor 1; SQCLC, squamous cell lung cancer; PDX, patient-derived xenograft.
See this image and copyright information in PMC

Comment on

  • Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. Malchers F, et al. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217. J Clin Invest. 2023. PMID: 37606995 Free PMC article.

References

    1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48. 10.3322/caac.21763 - DOI - PubMed
    1. Araghi M, Mannani R, Heidarnejad Maleki A, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int 2023;23:162. 10.1186/s12935-023-02990-y - DOI - PMC - PubMed
    1. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. 10.1200/JCO.21.01626 - DOI - PubMed
    1. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93. 10.1126/scitranslmed.3001451 - DOI - PMC - PubMed
    1. Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013;31:731-7. 10.1200/JCO.2012.43.8622 - DOI - PubMed